Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ATM inact mut||Advanced Solid Tumor||predicted - sensitive||Radiotherapy||Clinical Study||Actionable||In a clinical study, treatment with radiotherapy resulted in greater therapeutic efficacy in advanced solid tumor patients harboring an ATM inactivating mutation (n=177) compared to those who harbored an ATM variant of unknown significance (n=180), demonstrating a significantly decreased 2-year cumulative incidence of irradiated progression, 13.2% versus 27.5% (p=0.001), respectively, and the greatest clinical benefit was observed in tumors with bi-allelic ATM inactivating mutations (PMID: 32726432).||32726432|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT01898104||Phase Ib/II||Capecitabine + Radiotherapy Radiotherapy + Valproic acid Capecitabine + Radiotherapy + Valproic acid Radiotherapy||Preoperative Valproic Acid and Radiation Therapy for Rectal Cancer (V-shoRT-R3)||Recruiting||ITA||0|
|NCT01928589||Phase Ib/II||Radiotherapy||Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer||Recruiting||USA||0|